Stockreport

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer

TAKEDA PHARMA  (TKPYY) 
NASDAQ:AMEX Investor Relations: takeda.com/investors
PDF – In Patients with Brain Metastases at Baseline, ALUNBRIG Reduced the Risk of Progression in the Brain or Death by 73 Percent – – Intracranial Ef [Read more]